Keigo Gohda
Nishinomiya-hama, 6638241, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
A Review on Farnesoid X Receptor (FXR) Modulators Focusing on Benzimidazole Scaffold.
Journal: Molecules (Basel, Switzerland)
Published: November 22, 2025
FLG249 Exhibits FXR Antagonist Activity by Inducing Dissociation of Both Corepressors and Coactivators from FXR.
Journal: Biological & pharmaceutical bulletin
Published: July 16, 2025
Understanding of ATP-lid conformational dynamics in the N-terminal domain of Hsp90 and its mutants by use of a computational biochemistry approach.
Journal: Journal of biomolecular structure & dynamics
Published: April 07, 2025
Computational Elucidation of Possible Contributors to Formation and Stabilization of ATP-Lid Down-Conformation in the N-Terminal Domain of Hsp90.
Journal: Proteins
Published: February 27, 2025
FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGE2-EP4 Axis in BMP-2-Induced Mouse Mesenchymal Stem Cells.
Journal: Molecules (Basel, Switzerland)
Published: November 14, 2024
FXR Antagonist FLG249 Lowers Hepatic Triacylglycerol and Serum Cholesterol Level in High-Fat Diet-Induced Obese Mice.
Journal: Biological & pharmaceutical bulletin
Published: August 13, 2024
Discovery of FXR/PPARγ dual partial agonist.
Journal: Bioorganic & medicinal chemistry
Published: February 03, 2023
Conformational Analysis of the Loop-to-Helix Transition of the α-Helix3 Plastic Region in the N-Terminal Domain of Human Hsp90α by a Computational Biochemistry Approach.
Journal: Journal of chemical information and modeling
Published: October 24, 2022
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.
Journal: ACS medicinal chemistry letters
Published: December 06, 2020
Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
Journal: Bioorganic & medicinal chemistry letters
Published: December 03, 2020
N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR).
Journal: Bioorganic & medicinal chemistry
Published: March 26, 2020
Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
Journal: Molecules (Basel, Switzerland)
Published: October 12, 2019
Last Updated: 09/26/2026